Revenue segments as reported by the company.

Pharmaceutical

Animal Health

Other Revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Restructuring costs

Other (income) expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Merck

Merck & Co., Inc. engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Kenilworth, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Merck reports robust Q4 earnings, eyes growth through innovation

Merck's Q4 2022 performance reflects strong revenue growth and strategic advancements across key therapeutic areas, positioning the company for future success.
While facing challenges such as patent estate concerns and competitive pressures, Merck's focus on innovation and partnerships presents opportunities for sustained growth.
Analyst inquiries and executive responses during the earnings call highlight the company's commitment to transparency, patient outcomes, and shareholder value.

Merck reports robust Q1 earnings, eyes growth in oncology and vaccines

Merck's Q1 performance reflects strong revenue growth driven by oncology and vaccines, with a raised full-year guidance and focus on pipeline advancements.
The company's strategic strengths lie in its focus on compelling science, value alignment in business decisions, and commitment to innovation.
Challenges include potential impacts of EU legislation, post-KEYTRUDA LOE growth strategies, and navigating regulatory complexities for new treatments.
Opportunities in expansion in China, revenue diversification, innovative combination therapies, and protective treatment strategies position Merck for future growth.

Merck reports robust Q2 earnings, focuses on growth opportunities

Merck's Q2 performance showcased strong earnings driven by Oncology and Vaccines growth
Despite challenges like regulatory concerns and price pressures, the company remains focused on innovation
Opportunities lie in expanding KEYTRUDA's reach in cancer indications and advancing in immunology
Overall, Merck's strategic acquisitions and commitment to growth position it well for the future

Merck reports robust Q3 earnings, eyes growth in precision medicine

Merck's Q3 2023 Earnings Call highlighted strong revenue growth, pipeline advancements, and increased full-year revenue guidance. The company's strategic focus on key therapeutic areas and precision medicine approaches positions it for continued success and innovation.

Merck reports robust Q4 earnings, eyes growth through strategic investments

Merck's strong Q4 performance was driven by KEYTRUDA and Vaccines, with positive revenue guidance for 2024. The company remains focused on R&D advancements, strategic investments, and shareholder value. Challenges include managing expenses and maximizing market opportunities.

Merck reports robust Q1 earnings, eyes growth in innovative treatments

Merck's Q1 performance reflects strong revenue growth, operational efficiency, and a positive outlook for future earnings.
The company's focus on innovation, strategic investments, and commitment to patient access position it well for long-term success.
Challenges in pipeline differentiation and market competition require continued strategic planning and differentiation strategies.
Opportunities in new treatment areas, market expansion, and upcoming events offer avenues for sustained growth and market leadership.

Merck reports robust Q2 earnings, eyes future drug launches

Merck's Q2 earnings call highlighted strong financial performance, innovative product launches, and confidence in future growth. The company addressed analyst inquiries, emphasizing long-term pipeline growth and short-term financial guidance while expressing gratitude for investor support.

Merck reports solid Q3 earnings, eyes growth through diversification

Merck's Q3 2024 performance reflects revenue growth driven by key products and clinical advancements, despite regional sales variations and inventory challenges.
The company's strengths in diversification, clinical progress, and strategic investments position it well for future growth and competitive edge in the market.
While facing challenges in specific product sales and clinical trials, Merck has opportunities to capitalize on its strengths, expand offerings, and drive sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

AbbVie

Johnson & Johnson

The size of the pharmaceutical industry in the U.S. in 2023 was estimated to be nearly $575 billion, with an anticipated compound growth rate of about 5.5% through 2030. This key component of the healthcare sector includes both small biotech firms working to develop specialized treatments and much larger, established companies engaging in a wide array of health-related operations.

Best Pharma Stocks for Long-Term Investors: Growth and Dividends

Dominion Energy

Procter & Gamble

Walmart

Exxon Mobil

24/7 Wall St. Insights Dividend stocks will get a solid tailwind from falling interest rates.

5 Blue Chip Dividend Stocks to Own If You Had to Hold Them Forever

Pfizer

There's doubtlessly some coming uncertainty for both, but the prices are right.

2 Incredibly Cheap Big Pharma Stocks to Buy Now

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New Data to be Presented at IDWeek 2024 Reinforce Merck's Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio.

New Data to be Presented at IDWeek 2024 Reinforce Merck's Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio

Dublin, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The "Activated Polyethylene Glycol Market Report: Trends, Forecast and Competitive Analysis to 2030" report has been added to ResearchAndMarkets.com's offering. The global activated polyethylene glycol market is expected to reach an estimated $162 million by 2030 with a CAGR of 2.4% from 2024 to 2030. The major drivers for this market are the chemical and pharmaceutical sectors are expanding quickly, rapid advancement in molecular biology and biotechnology, as well as, growing acceptance of water-based paints, varnishes, and inks due to their wider range of applications in the automotive and building sectors. The future of the global activated polyethylene glycol market looks promising with opportunities in the pharmaceutical intermediate and medical device markets.

Activated Polyethylene Glycol Market Report 2024 - Trends, Forecast and Competitive Analysis to 2030, with Profiles of Leading Players NOF, JenKem Technology, Laysan Bio, Merck Creative and PEGWorks

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-689 trial evaluating KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, as a perioperative treatment for patients newly diagnosed with stage III or IVA, resected, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) met its primary endpoint of event-free survival (EFS). The study evaluated KEYTRUDA as neoadjuvant therapy, then continued.

Merck's KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma

Dublin, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The "Flavonoids Market Report by Type, Form, Application, and Region 2024-2032" report has been added to ResearchAndMarkets.com's offering. The global flavonoids market size reached US$ 1.3 Billion in 2023. Looking forward, the market is expected to reach US$ 2.1 Billion by 2032, exhibiting a growth rate (CAGR) of 5.5% during 2023-2032. Flavonoid is a natural polyphenolic compound with variable phenolic structures. It is a biologically active compound that adds pigment to fruits and vegetables, such as grapes, citrus fruits, peppers, onions, kale and dill. Chalcones, flavones, isoflavonoids, flavanones, anthoxanthins and anthocyanins are the commonly available flavonoids that are extracted from the barks, roots, stems and flowers of the plants. They are widely used as coloring and ultraviolet (UV) protection agents in functional food, dietary supplements and pharmaceutical and cosmetic products. They exhibit anti-aging, anti-edema, antioxidant and anti-inflammatory properties. Flavonoids smoothen and moisturize the skin, prevent the formation of wrinkles and promote collagen synthesis. They can also inhibit cancer cell growth, cure stomach ulcers and prevent infections in the body.

Flavonoids Market Report 2024-2032, with Profiles of Key Players Alchem, Bordas, Cayman Chemical, Extrasynthese, Flavon USA, Indena, Inodfine Chemical, Nutralliance, Merck and Quercis Pharma

Merck's recent decline is due to reduced profit guidance and FDA decisions, but shares are at a support level that is likely to hold. Keytruda remains a key revenue driver, with potential for continued growth and extended patent protection through a subcutaneous formulation. Strategic acquisitions are broadening Merck's pipeline and should reduce its reliance on Keytruda, despite the short-term profit impacts.

Merck Is At Support And Should Go Higher (Technical Analysis)

Boeing

JPMorgan Chase & Co

They may technically be blue chips, but that doesn't necessarily make them your best bets at their discounted prices.

Is It Time to Buy September's Worst-Performing Dow Jones Stocks?

Amgen

Amazon

Salesforce

Cisco Systems

Chevron

Disney

Dow Inc

Goldman Sachs

Honeywell

Intel

Coca-Cola

Microsoft

NIKE

Verizon

"The Dow® [adds a stock] if the company has an excellent reputation,

Buy 2 October Dogs Of The Dow And Watch 5 More

Adobe

Lam Research

By most accounts, the stock market has had a very good 2024. The S&P 500 has provided a total return so far of 20.6%.

3 Bargain Stocks Positioned for Gains After Missing 2024's Rally

Eli Lilly

The pharmaceutical industry plays a crucial role in most of our everyday lives.

3 Top Pharma Stocks to Buy in October 2024

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the completion of the acquisition of CN201 from Curon Biopharmaceutical (Curon), a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases. “By actively depleting B-cells, CN201 offers applications spanning both B-cell malignancies and autoimmune diseases. We look forward to building upon the foundational work started by the Cur.

Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31.

Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31

The phase III KEYFORM-007 study, evaluating Merck's Keytruda plus favezelimab for treating metastatic colorectal cancer, fails to meet the primary endpoint.

MRK's Keytruda Combo Fails in Phase III Colorectal Cancer Study

Evaxion Biotech A/S

Evaxion Biotech A/S EVAX inked an option and licensing deal with Merck & Co., Inc MRK for two preclinical vaccine candidates.

Evaxion Biotech Partners With Merck To Expand Vaccine Development

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that new data highlighting the long-term efficacy and safety of tulisokibart (MK-7240), an investigational humanized monoclonal antibody directed to a novel target, tumor necrosis factor (TNF)-like cytokine 1A (TL1A), in ulcerative colitis (UC) and Crohn's disease (CD) will be presented at the United European Gastroenterology (UEG) Week 2024 Congress in Vienna, Austria. Long-t.

Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024

Merck & Co.'s said a late-stage trial of its blockbuster cancer drug Keytruda in combination with favezelimab failed to meet the main goal of overall survival (OS) as a treatment for a type of colon cancer.

Merck says trial of combination treatment for colon cancer failed to meet main goal

Merck said on Wednesday its therapy did not meet the main goal of a late-stage trial evaluating it in patients with a type of colorectal cancer.

Merck's colorectal cancer therapy fails late-stage trial

RAHWAY, N.J.--(BUSINESS WIRE)--Update on KEYFORM-007 Trial Evaluating Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1+ MSS mCRC.

Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck's KEYTRUDA Receives New Approvals in Japan for Certain Patients With NSCLC and Radically Unresectable Urothelial Carcinoma.

Merck's KEYTRUDA® (pembrolizumab) Receives New Approvals in Japan for Certain Patients With Non-Small Cell Lung Carcinoma (NSCLC) and Radically Unresectable Urothelial Carcinoma

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the expansion of the newly USDA-approved NOBIVAC® NXT vaccine platform to include a best in class solution to protect cats against one of the most common feline infectious diseases, feline leukemia virus (FeLV). The vaccine is expected to be available at veterinary clinics and hospitals nationwi.

Merck Animal Health Announces Expansion of NOBIVAC® NXT Platform with the First and Only RNA-Particle Technology Vaccine for Feline Leukemia Virus

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers.

MRK Gets Positive CHMP Nod for Keytruda in Two Gynecologic Cancers

Declining estimates and the recent price drop make investors skeptical about holding MRK stock.

News for Merck Stock (MRK)